Cannabinoid Hyperemesis Syndrome, 2016 to 2022.

ABSTRACT:

Importance

Cannabinoid hyperemesis syndrome (CHS), ie, recurrent emesis from chronic cannabis use, is increasingly observed in emergency departments (EDs), yet population-level estimates and sociodemographic correlates remain underexplored.

Objective

To estimate CHS prevalence in US EDs, assess trends from 2016 to 2022, and examine sociodemographic associations.

Design, setting, and participants

This cross-sectional study, using data from the Nationwide Emergency Department Sample (approximately 85% of annual US ED visits) examined patients aged 12 years and older. Patients with ED visits related to pregnancy, gastroparesis, or chemotherapy were excluded.

Main outcomes and measures

ED visits were grouped into 4 categories. Primary outcome was comparative tempor

SUBMITTER: Swartz JA 

PROVIDER: S-EPMC12645340 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature